Zyversa Therapeutics, Inc.4月14日成交额为646.36万美元

市场透视2025-04-15

美东时间2025年4月14日，Zyversa Therapeutics, Inc.（ZVSA.US）成交额为646.36万美元，成交额较昨日增加836.63%，当日成交量为644.81万股。Zyversa Therapeutics, Inc.（ZVSA.US）于2025年4月14日涨10.39%，报0.85美元，该股过去5个交易日涨46.05%，年初至今跌19.81%，过去60日跌37.04%。|...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527830244?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-15 11:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2527830244","market":"us","top_or_hot":-1,"title":"Zyversa Therapeutics, Inc.4月14日成交额为646.36万美元","media":"市场透视","content":"<div>\n<p>美东时间2025年4月14日，Zyversa Therapeutics, Inc.（ZVSA.US）成交额为646.36万美元，成交额较昨日增加836.63%，当日成交量为644.81万股。Zyversa Therapeutics, Inc.（ZVSA.US）于2025年4月14日涨10.39%，报0.85美元，该股过去5个交易日涨46.05%，年初至今跌19.81%，过去60日跌37.04%。|...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110524a6bab9e3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zyversa Therapeutics, Inc.4月14日成交额为646.36万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZyversa Therapeutics, Inc.4月14日成交额为646.36万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-15 11:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110524a6bab9e3&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间2025年4月14日，Zyversa Therapeutics, Inc.（ZVSA.US）成交额为646.36万美元，成交额较昨日增加836.63%，当日成交量为644.81万股。Zyversa Therapeutics, Inc.（ZVSA.US）于2025年4月14日涨10.39%，报0.85美元，该股过去5个交易日涨46.05%，年初至今跌19.81%，过去60日跌37.04%。|...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110524a6bab9e3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110524a6bab9e3&s=b","article_id":"2527830244","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415110524a6bab9e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2527830244","pubTimestamp":1744686321,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美东时间2025年4月14日，Zyversa Therapeutics, Inc.成交额为646.36万美元，成交额较昨日增加836.63%，当日成交量为644.81万股。Zyversa Therapeutics, Inc.于2025年4月14日涨10.39%，报0.85美元，该股过去5个交易日涨46.05%，年初至今跌19.81%，过去60日跌37.04%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-14|646.36万|836.63%|644.81万|#|2025-04-11|69.01万|-88.73%|78.63万|#|2025-04-10|612.09万|180.03%|543.84万|#|2025-04-09|218.58万|-98.43%|226.43万|#|2025-04-08|1.39亿|255837.39%|1.14亿|ZyVersa Therapeutics Inc 是一家临床阶段的生物制药公司，利用专有技术为医疗需求未得到满足的慢性肾脏或炎症性疾病患者开发药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","BK4139":"生物科技","ZVSA":"ZyVersa Therapeutics, Inc."},"translate_title":"Zyversa Therapeutics, Inc. turnover of $6,463,600 on April 14","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ZVSA":0.9},"content_text":"美东时间2025年4月14日，Zyversa Therapeutics, Inc.（ZVSA.US）成交额为646.36万美元，成交额较昨日增加836.63%，当日成交量为644.81万股。Zyversa Therapeutics, Inc.（ZVSA.US）于2025年4月14日涨10.39%，报0.85美元，该股过去5个交易日涨46.05%，年初至今跌19.81%，过去60日跌37.04%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-14|646.36万|836.63%|644.81万|#|2025-04-11|69.01万|-88.73%|78.63万|#|2025-04-10|612.09万|180.03%|543.84万|#|2025-04-09|218.58万|-98.43%|226.43万|#|2025-04-08|1.39亿|255837.39%|1.14亿|ZyVersa Therapeutics Inc 是一家临床阶段的生物制药公司，利用专有技术为医疗需求未得到满足的慢性肾脏或炎症性疾病患者开发药物。 该公司拥有两个专有的全球许可药物开发平台，即Cholesterol Efflux MediatorTM，VAR 200（2-羟丙基-β-环糊精）是一种处于临床开发阶段的用于治疗肾脏疾病的注射药物。 IC 100 是一种单克隆抗体炎性体 ASC 抑制剂，处于临床前开发阶段，用于治疗炎症。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527830244","isCrawlerRequest":true}